Thank you @dgsomucla for hosting our CMO Dr. Rob Schott to discuss how our innovative approach supports body fat loss while preserving muscle. Learn more about our research:

We’re sharing a corporate update at #JPM25 highlighting our clinical development progress for our lead investigational therapy and our full pipeline of innovative Controlled Metabolic Accelerators. Read more:

Last week, our CEO Dr. Jayson Dallas shared how Rivus is aiming to "be the best in #cardiometabolic disease" to stand out amid the crowded landscape during a panel at #BIF24. Thank you @IamBiotech for hosting this insightful discussion!

During #HFSA2024 today, we presented new positive findings from our Phase 2a trial of our experimental therapy, which is being studied as a potential disease-modifying treatment for #HFpEF. Learn more:

We’re presenting data from our Phase 2a HuMAIN trial for #HFpEF at @HFSA 2024, which met the primary endpoint of weight loss in patients with obesity-related heart failure. Learn more:

We're pleased to welcome Tom O’Neil as CFO & Erin Lavelle to our Board of Directors. Their expertise will be invaluable as we advance our innovative pipeline to address critical unmet needs in cardiometabolic diseases including #HFpEF and #MASH. Read more:

Our Phase 2a HuMAIN trial met primary & secondary endpoints, supporting potential for our investigational therapy to be the first disease-modifying treatment for #HFpEF by enabling fat-specific weight loss. More data to be presented at #HFSA. Learn more:

Our approach aimed at increasing energy expenditure could improve cardiometabolic health & lead to fat-specific weight loss, avoiding the reductions in muscle mass that pose a persistent challenge with current weight loss medicines. Read more @biospace:

Our investigational Controlled Metabolic Accelerator could potentially slow #HFpEF disease progression by boosting metabolism & reducing body fat. Details of our Phase 2a trial are now available in @escardio. Learn more:

Obesity & other metabolic diseases are major risk factors for #MASH. This Global Fatty Liver Day, we're raising awareness about the urgent need to expand treatment options for MASH. Learn about our approach to treating metabolic diseases: #LiverTwitter

Our CEO Dr. Jayson Dallas is sharing how our next-gen approach to treating metabolic diseases that are underserved by existing therapeutic options is poised to shake up the current treatment paradigm. Read more from @fwpharma:

We are celebrating five years of advancing our first-in-class approach which aims to fundamentally change how metabolic diseases driven by obesity are treated. Thank you to our incredible team and partners for making it possible!

Our CEO, Dr. Jayson Dallas, shares with @PharmaVoice how our unique therapeutic approach is focused on metabolic rate, not just weight loss, and has the potential to redefine the treatment landscape for #CardiometabolicDiseases. Read more:

Today at #JPM24 we shared our vision to improve cardiometabolic health with a new class of investigational therapies focused on energy expenditure instead of energy intake by controlling acceleration of basal metabolism. We look forward to continuing the conversation.

We've completed enrollment for our Ph2a trial in patients with #obesity & #heartfailure. More details on how we're transforming the treatment of obesity & metabolic diseases in our corporate update at #JPM24. Read more: #JPM2024

We're advancing our lead clinical program aimed at inducing fat-specific weight loss & improving metabolic health w/ a Ph2b trial initiation in patients w/ #obesity & Type 2 #diabetes at risk of #MASH & the expansion of our leadership team. Read more:

RT @LancetGastroHep: New research - Noureddin et al - Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fat…

Our first-in-class investigational therapeutic has shown exciting promise in patients with #NAFLD and #obesity. Positive results from our Phase 2a study are now published in @LancetGastroHep. Read more:

Excited to share that our Board Chair, Jayson Dallas, MD, has been appointed CEO to lead the company into our next stage of development. Allen Cunningham will transition into the role of COO with oversight of operations and clinical development for HU6.

Our team is developing new therapies with our innovative Controlled Metabolic Accelerators (CMAs) like HU6 to address obesity, a primary driver of heart disease. #CMAs leverage mitochondrial uncoupling to reduce fat & conserve muscle. #AmericanHeartMonth #CardioMetabolicHealth